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ABSTRACT 
Currently, it is of interest to improve the oral absorption of poorly water soluble therapeutic 
agents using supersaturating formulations. Understanding crystallization kinetics of supersaturated 
drug solutions is central to the design and evaluation of such formulations.  Bile salts have drawn 
increasing attention in this context as they serve important roles in biorelevant dissolution media, 
in vivo, and have been shown to slow down the crystallization of active pharmaceutical ingredients. 
The goal of this study was to evaluate the impact of bile salt monomers and micelles on the 
crystallization of telaprevir, a poorly water soluble drug, from aqueous solution. To better describe 
the crystallization driving force in the presence of the bile salts, a side-by-side diffusion cell was 
used to evaluate telaprevir mass flow rate, and hence solute activity, in the absence and presence 
of different bile salts. The effectiveness of monomeric and miceller bile salts as crystallization 
inhibitors was then evaluated by performing crystallization induction time experiments at constant, 
activity-based supersaturation.  The six most abundant biologically relevant bile salts were 
investigated (sodium taurocholate, sodium taurodeoxycholate, sodium taurochenodeoxycholate, 
sodium glycocholate, sodium glycodeoxycholate, and sodium glycochenodeoxycholate). All six 
bile salts exhibited nucleation inhibition properties in both homogenous supersaturated telaprevir 
solutions and highly supersaturated telaprevir solutions containing a second phase. The ability to 
retard telaprevir nucleation, however, varied amongst the bile salts and also depended on the 
aggregation state. Monomeric bile salts were found to be effective crystallization inhibitors. At 
higher bile salt concentrations, trihydroxy bile salts showed better inhibition compared to 
dihydroxy bile salts. These results highlight the importance of considering the composition of the 
test medium used to evaluate product performance, in particular in the context of evaluating 
crystallization kinetics. 
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INTRODUCTION 
 With an increasing number of poorly water soluble compounds in pharmaceutical 
developmental pipelines,1, 2 there has been considerable focus on formulation strategies that 
elevate compound solubility without decreasing the apparent  permeability across the 
gastrointestinal (GI) membrane. In general, this involves utilization of a higher energy state of the 
compound,3, 4 such as an amorphous solid dispersion (ASD) formulation. In this instance, a highly 
supersaturated solution is created upon dissolution, where the resulting concentration gradient then 
facilitates absorption of the drug across membranes. Due to its unstable thermodynamic nature, 
supersaturated solutions tend to crystallize and lose the enhanced solubility advantage.  Thus, the 
key determinant dictating the success of these strategies is the ability to maintain supersaturation 
and avoid crystallization over biologically relevant timeframes, thus allowing drug transfer across 
the GI membrane and maximizing the extent of oral absorption.   
 Depending on the magnitude of supersaturation created upon dissolution, the two 
major kinetic events of crystallization, nucleation and crystal growth, will take place and consume 
the enhanced solution concentration generated by the employed formulation strategy. Additives 
are often used in commercial formulations to serve as crystallization inhibitors. A wide variety of 
structurally different polymers has been shown to stabilize both the amorphous state5-7 and highly 
supersaturated solutions5, 8-10 of poorly soluble drugs. Besides the commonly employed polymeric 
additives, bile salts, which are endogenous surfactants, have attracted the interest of researchers 
since they show potential as crystallization inhibitors.11-13 Bile salts, the main product of 
cholesterol metabolism, form mixed micelles with phospholipids and phospholipid hydrolysis 
products and are present in the upper human intestine. Bile salt molecules consist of a rigid steroid 
ring system, with hydroxyl groups distributed on one side, exhibiting facial polarity. Due to their 
unique molecular structure, bile salts exhibit step-wise aggregation,14, 15 dissimilar to ordinary 
aliphatic surfactants, and show broader critical micelle concentration ranges.16 The most abundant 
biologically relevant bile salts found in human intestinal fluids are sodium taurocholate (STC), 
sodium taurodeoxycholate (STDC), sodium taurochenodeoxycholate (STCDC), sodium 
glycocholate (SGC), sodium glycodeoxycholate (SGDC), and sodium glycochenodeoxycholate 
(SGCDC),17 with reported critical micelle concentration (CMC) values in the range of 2 to 
12mM.16, 18 The trihydroxy bile salts are generally more water soluble and have higher CMC values 
than the dihydroxy bile salts. The total concentration and composition of bile salts in the GI tract, 
however, has been reported to vary to a great extent from person to person.19 
 Chen et al.12 first demonstrated differences between bile salts and general aliphatic 
surfactants in terms of crystallization inhibition. At surfactant concentrations below the CMC, 
sodium taurocholate (STC) was noted to slow down solution crystallization of a group of 
structurally diverse active pharmaceutical ingredients (APIs), while sodium dodecyl sulfate (SDS) 
showed a tendency to promote solution crystallization. Two other bile salts, sodium glycocholate 
(SGC) and sodium glycodeoxycholate (SGDC), were also revealed to be effective crystallization 
inhibitors for celecoxib and nevirapine in monomer form. Recently, Li et al.13 further explored the 
crystallization inhibitory ability of 13 bile salts at a concentration below their CMC in 
supersaturated solutions of celecoxib, nevirapine and flibanserin.  Most bile salts studied slowed 
down crystallization of these fast crystallizing compounds, though the extent of inhibition varied 
amongst the bile salts, showing that bile salts are not interchangeable in the context of 
crystallization inhibition. These studies showed the crystallization inhibitory effects of monomeric 
bile salts towards a variety of APIs; however, bile salts exist in human intestinal fluid (HIF) as 
mixed micelles which contain other biorelevant species such as lecithin, and there is limited 
information about how bile salt aggregation level differences impact the crystallization inhibition 
properties of bile salts. In addition, the stabilizing ability of bile salts in more complex solutions, 
that is highly supersaturated solutions in which liquid liquid or glass liquid phase separation (LLPS 
or GLPS) has occurred, has not yet been explored. These more complex solutions are of relevance 
in the context of ASDs which have been shown to dissolve to produce an amorphous drug-rich 
phase of sub-micron dimensions through the process of LLPS20, 21 (or GLPS if the Tg of the water 
saturated amorphous drug is higher than temperature of the dissolution process22). Moreover, the 
mechanism for the anti-crystallization properties of bile salts has not been studied extensively. It 
is important to understand the mechanism and to determine if it is complementary to other anti-
crystallization excipients such as polymers. 
 An inconsistency between the concentration-based supersaturation ratio and 
thermodynamic activity ratio, which is the fundamental driving force for crystallization, has been 
observed for some systems that contain solubilizing additives.23 In a previous study,24 we 
addressed this issue by scrutinizing the impact of the six most abundant biorelevant bile salts, in 
both monomeric and micellar form, on solution thermodynamics, and a supersaturation calibration 
method was developed. It was further noted that bile salts show different patterns of interaction 
with supersaturated telaprevir solutions, with trihydroxy bile salts having less effect on telaprevir 
solution thermodynamics than dihydroxy bile salts. Based on our knowledge of the impact of bile 
salts on telaprevir solution thermodynamics, herein, a systematic evaluation of the potential role 
of both monomeric and micellar bile salts as crystallization inhibitors was carried out by 
performing crystallization induction time experiments at the same activity-based supersaturation 
in the presence of six taurine/glycine conjugated dihydroxy (STDC, SGDC, STCDC, and SGCDC) 
and trihydroxy (STC and SGC) bile salts.  
MATERIALS  
 Telaprevir was obtained from Attix Pharmaceuticals (Toronto, Ontario, Canada) and 
ChemShuttle (CA). Hydroxypropyl methyl cellulose acetate succinate grade AS-MF (HPMCAS-
MF) was obtained from Shin Etsu Chemical Co., Ltd (Tokyo, Japan). Sodium taurocholate 
(practical grade, MP Biomedicals, LLC, OH), sodium glycocholate &KHP-,PSH[ ,QW¶O
,QF ,/ VRGLXP WDXURGHR[\FKRODWH  &KHP-,PSH[ ,QW¶O ,QF ,/ VRGLXP
JO\FRGHR[\FKRODWH6LJPD02), sodium taurochenodeoxycholate (98%, Sinova Inc., MD) 
and sodium glycochenodeoxycholate &KHP-,PSH[,QW¶O,QF., IL) were used as received. 
Molecular structures of telaprevir and the six bile salts are shown in Figure 1. A regenerated 
cellulose membrane with a molecular weight cutoff (MWCO) of 6-8 kDa was acquired from 
Spectrum Laboratories, Inc. (Rancho Dominguez, CA). The aqueous media used in all experiments 
was 50mM pH 6.5 sodium phosphate buffer. 
METHODS  
Supersaturation Determination. 
 To better design formulations with improved oral absorption, the fundamentals of 
crystallization kinetics must be considered. Solution crystallization is a thermodynamically 
favored event when a chemical potential difference between the solute and its crystalline state 
exists.25 The driving force, supersaturation į, can be quantified and expressed as the activity ratio 
of the solute to its equilibrium crystalline state:26 
  ߜ ൌ ߤ െ ߤιܴܶ ൌ  ܽܽι (1) 
where ߤ is the chemical potential of the solute, ܴ is the ideal gas constant, ܶ is temperature, and ܽ 
is the solute activity. ι indicates the property at standard state (defined as solute in a solution in 
equilibrium with the stable crystalline form in this study). A side-by-side diffusion cell (PermeGear, 
Inc. Hellertown, PA) was used to evaluate the supersaturation level of telaprevir in the absence 
and presence of different bile salts (at 1.86 mM or 12 mM bile salt concentrations). The basic 
concepts and methods were as described in our previous study.24 The mass flow rates of telaprevir, 
F, are directly proportional to solute activity. The ratio of solute mass flow rate in the solution of 
interest to the mass flow rate of the corresponding standard state system (solute in a solution in 
equilibrium with crystalline state in this study) yields the fundamental supersaturation:  
 
ܨܨι ൌ ܽܽι ൌ ߜ (2) 
With the mass flow rate data from our previous study24 and equation (2), telaprevir supersaturation 
level in the absence and presence of bile salts can be determined from Figure 2.  In the following 
FU\VWDOOL]DWLRQ VWXG\ WZR VXSHUVDWXUDWLRQ OHYHOV ZHUH WKHQ FKRVHQ į   11.5 which yields a 
homogeneous supersaturated solution ZKHUHWHODSUHYLULVPROHFXODUO\GLVVROYHGDQGį 8 which 
represents a high supersaturation condition where a glassy second phase of telaprevir is present 
since the amorphous solubility is just exceeded.24  
Crystallization Induction Time Measurements. 
 Crystallization induction time measurements were used to evaluate bile salt anti-
crystallization properties for supersaturated telaprevir solutions. Supersaturated telaprevir 
solutions were prepared by titrating concentrated methanolic telaprevir stock solution (12 or 20 
mg/mL) to 50mL of 50 mM pH 6.5 sodium phosphate buffer with or without predissolved bile 
salts or polymer, stirred at 300 rpm at 37 °C. Bile salts were present in solution at a concentration 
of 1.86 mM or 12 mM. Solutions with a higher bile salt concentration (18mM) for STC and SGC 
were as well prepared to further study the role of micellar trihydroxy bile salts. For comparative 
purposes, HPMCAS-MF was used at a concentration of 5ȝg/mL and 1mg/mL. The onset of 
telaprevir crystallization can be detected from a sudden decrease in the UV signal at a maximum 
absorption wavelength (270nm in this study) due to the consumption of telaprevir solution 
concentration when nucleation took place.  Owing to the scattering effect from the newly form 
crystals, an increase in the UV signal at a non-absorbing wavelength (370nm in this study) can 
also be detected at the same instance. The time point at which crystallization is detected is then 
defined as the crystallization induction time tind (example plot shown in Figure 3). The change in 
UV signal was monitored using an SI Photonics UV/vis spectrometer (Tuscon, Arizona), fiber-
optically coupled with a 1 cm or 0.5cm path length dip probe.  
 The measured crystallization induction time, tind, in this study is a combination of the 
nucleation induction time, tn, the nucleation time for critical nucleus formation,
25 and a growth 
period, tg, the time needed for crystals to grow to a detectable size:
10, 27, 28 
 ݐ௜௡ௗ ൌ ݐ௡ ൅ ݐ௚ (3) 
Induction time measurements in this study were performed in triplicate, and the error bars in each 
figure represent standard deviation.  
Surface Tension Measurements. 
 The critical micelle concentrations of STC and SGDC in the absence and presence of 
telaprevir were determined by measuring solution surface tension using a Processor Tensiometer 
K12 (Krüss, Germany) by the Wilhelmy plate method. All measurements were performed with 
50mL of predissolved bile salt buffer solution at 37°C, and the temperature was maintained within 
± 0.5 °C by a circulating waterbath. For measurements with telaprevir, methanolic telaprevir stock 
solution (12mg/mL) was titrated into the predissolved bile salt buffer solution to reach a telaprevir 
concentration of 60ȝg/mL, with thorough mixing. The accuracy of all measurements was within 
±0.05 mN/m. 
Zeta Potential Measurements. 
 The zeta potentials of the telaprevir-rich colloidal nanodroplets formed upon glass-
liquid phase separation (GLPS) in solutions in the presence of monomeric bile salts were measured 
using a Nano-Zetasizer (Nano ZS, Malvern, Westborough, MA). Highly supersaturated solutions 
with telaprevir-rich nanodroplets (180 ȝg/mL) were obtained by titrating concentrated methanolic 
telaprevir stock solution (12 mg/mL) into 10mL of 50 mM pH 6.5 sodium phosphate buffer with 
1.86mM bile salts, stirred at 300rpm at 37°C, until the solution became turbid indicating phase 
separation. Solutions were evaluated using an optical microscope under cross-polarized light, and 
no visible crystals could be observed. The zeta potential of the telaprevir drug-rich phase with no 
bile salt was also measured for reference.  
RESULTS  
Crystallization Induction Time - Effect of Bile Salt Concentration 
 Crystallization induction times were determined at constant supersaturation level to 
understand the inhibitory ability of different bile salt aggregation levels. In the absence of bile salts, 
homogeneous telaprevir supersaturated solutions į  crystallized within 30 minutes. Figure 
4 shows that all six bile salts slow down crystallization of homogeneous supersaturated solutions, 
regardless of the bile salt aggregation levels.  At 1.86mM bile salt concentration, bile salts maintain 
solution supersaturation for over 16 hours and no observable crystallization events were detected. 
Besides the UV-vis spectroscopy method, solutions were also checked with an optical microscope 
under cross-polarized light and no visible crystals could be observed. As bile salt concentration 
increases to 12mM, trihydroxy bile salts (STC and SGC) and SGCDC maintain solution 
supersaturation over 16 hours, having comparable inhibitory ability to their monomeric form. 
Dihydroxy bile salts (STDC, SGDC, and STCDC) on the other hand, are less effective compared 
to their monomeric forms, delaying the occurrence of telaprevir crystallization to about 2 hours.  
 Meanwhile, highly supersaturated telaprevir solutions (į = 28.8) containing a drug-
rich amorphous phase, crystallized much faster compared to the homogeneous supersaturated 
solutions. Figure 5 shows that the presence of STC, SGC, STDC, and SGDC slowed down 
crystallization of highly supersaturated solutions containing telaprevir-rich amorphous phase. 
Solutions containing STCDC and SGCDC cannot reach the same supersaturation level due to 
partitioning of bile salts into telaprevir-rich phase.24 For the trihydroxy bile salts, STC and SGC, 
an increase in crystallization induction time was observed with increasing bile salt concentration. 
For dihydroxy bile salts, STDC and SGDC, an increase in bile salt concentration resulted in 
reduced crystallization induction time.  
 The CMCs of STC and SGDC, as representative trihydroxy and dihydroxy bile salts 
respectively, in the absence and presence of 60ȝg/mL telaprevir, were determined using surface 
tension measurements, and the results are summarized in Figure 6. Assuming the CMC values do 
not vary significantly amongst the trihydroxy and dihyhydroxy groups, and the concentration 
dependence of telaprevir is negligible, then it can be reasonably assumed based on these results 
that the majority of bile salts in solution at a concentration of 1.86mM are in monomeric form. In 
addition, micellar bile salts are most likely the dominant species at a bile salt concentration of 
12mM, given that it is well above their CMCs. The concentration dependence of bile salt 
crystallization inhibitory effect was examined in more depth with STC, the only bile salt present 
in commercial biorelevant media, at concentrations below its CMC and at constant supersaturation 
OHYHO į   . Figure 7 shows that the crystallization induction time increased as STC 
concentration increased. With the presence of minimal STC (0.47mM, less than 0.025% (w/w)), 
the crystallization induction time changed from within 30 minutes to approximately 3 hours, 
revealing the potential of STC as a crystallization inhibitor for amorphous formulations. This 
prolonged induction time is of relevance in the context of small intestinal transit time which have 
been reported to be around 3-4 hours.29 
Crystallization Induction Time - Effect of Drug Concentration and Solution Homogeneity  
 The impact of supersaturation level and solution homogeneity (single phase or 
containing amorphous nanodroplets) is summarized in Figure 8 and 9. Without any additives, the 
crystallization induction time decreased as drug concentration increased. This result is expected 
since both nucleation and crystal growth rates increase with higher crystallization driving force. 
However, these kinetic events appear to be more complicated as bile salts are introduced to the 
systems. Figure 8 shows the extent of bile salt retardation of telaprevir nucleation under constant 
bile salt concentration (1.86mM) as a function of telaprevir concentration. Overall, all six bile salts 
at monomeric levels are good crystallization inhibitors, as they all slow down telaprevir 
crystallization at į = 11.5 (homogeneous solution) and the induction time is increased to more than 
16 hours. Increasing the drug concentration to į = 28.8, where a telaprevir-rich amorphous phase 
was created, generally results in a decrease in induction time, and in these systems the inhibitory 
ability varies considerably amongst the different bile salts. Monomeric dihydroxy bile salts (STDC 
and SGDC) are more effective than monomeric trihydroxy bile salts (STC and SGC), with SGDC 
being the most effective crystallization inhibitor in the presence of the telaprevir-rich amorphous 
phase. 
 At 12mM bile salt concentration, the six bile salts slow down crystallization of 
homogeneous and heterogeneous (containing the telaprevir-rich amorphous phase) supersaturated 
solutions to different extents (Figure 9). The trihydroxy bile salts, STC and SGC, maintained 
supersaturation of the homogeneous solutions for over 16 hours, while their inhibitory effect 
decreased in the heterogeneous solutions with higher supersaturation. In contrast, the dihydroxy 
bile salts, STDC and SGDC, are less effective crystallization inhibitors but, interestingly, their 
inhibitory effect improved for the heterogeneous, more supersaturated solutions, in particular for 
SGDC. This is different from previous cases where crystallization induction times decreased as 
crystallization driving force increased, thus further mechanistic studies are warranted. 
Zeta Potential of the Telaprevir-rich Droplets 
Zeta potential measurements were conducted to understand the interactions of monomeric 
bile salts and the telaprevir-rich droplets formed when the concentration exceeds the amorphous 
solubility. Zeta potential, ȗ, is a measurement of the electric potential difference, with contributions 
from both physically adsorbed and chemically absorbed ions, at interfaces in solution.30 Since 
telaprevir is neutral in the buffer medium used in this study, the change in zeta potential upon 
addition of monomeric bile salt, which is negatively charged at the pH employed, serves as an 
indication of adsorption of bile salts at the telaprevir-rich droplet-water interface. Figure 10 
summarizes the zeta potential values of telaprevir-rich droplets in the absence and presence of six 
monomeric level bile salts.  The zeta potential of telaprevir-rich droplets in the absence of bile 
salts was -9.2 mV. A ~4-5 fold increase in the magnitude of zeta potential was observed with the 
addition of each of the six monomeric bile salts (1.86mM bile salt concentration), which implies 
adsorption of bile salts at the telaprevir-rich droplet-water interface.  A similar phenomena has 
been observed in a previous study with danazol, a poorly soluble API, in the presence of HPMCAS 
(a negatively charged polymer).31 
DISCUSSION 
Nucleation Inhibition Versus Growth Inhibition 
Induction time measurement is a well-established and commonly employed method to 
quantify nucleation. Induction time, tind, by definition, is a combination of the time needed for 
nuclei formation and the time needed for nuclei to grow to a detectable size. It has been common 
practice to measure induction time for nucleation kinetic studies,10, 27, 28 assuming the time required 
for critical nuclei formation is the dominant factor. As demonstrated in previous studies, it is 
possible to decouple the tg term in equation 3 with proper experimental design and hence have a 
better understanding of nucleation kinetics.32, 33 By determining seedless induction times and the 
seeded growth rates in the presence and absence of bile salts under similar experimental conditions, 
the relative nucleation rate in the presence and absence of the bile salt can be estimated:  
 
ܬܬ଴ ൌ ሺܴ଴ܴሻଷሺݐ௨ǡ଴ݐ௨ ሻସ (4) 
where J is the nucleation rate in the presence of bile salts, J0 is the nucleation rate in the absence 
of bile salts, R0/R is the mass growth rate in the absence of bile salts divided by the rate in the 
presence of bile salts, tu,0 is the unseeded induction time in the absence of bile salts and tu is the 
induction time in the presence of bile salts.  
 To confirm the assumption that tn of equation 3 is the dominant factor, and not the effect 
of the bile salts on growth rates, selected additional kinetic studies (growth rate measurements) 
were carried out with STC and SGC, the most commonly studied bile salts, and equation 4 was 
applied to decouple the nucleation and growth rates. From Figure 4, the induction time in the 
absence of bile salts was determined to be ~30 minutes and in the presence of STC or SGC the 
induction time was estimated to be more than 16 hours (960 minutes). From Figure 11, the mass 
growth rates in the absence and presence of bile salts were calculated by taking the slope of the 
concentration versus time data over the initial 10 minutes of the experiment. The mass growth rate 
of telaprevir without bile salts is 89.2 ȝg/min, and the mass growth rates in the presence of 1.86mM 
STC and SGC are 6.4 ȝg/min and 60.5 ȝg/min, respectively (telaprevir growth rate is slowed down 
by 14 fold and 1.5 fold, respectively). These values were used as input for equation 4, where J/J0 
was then estimated to be 2.5 × 10í for STC, and 2.9 × 10í for SGC. In other words, telaprevir 
nucleation rate is slowed down by at least 400 fold and 340,000 fold in the presence of 1.86mM 
STC and SGC, respectively.  It is evident that the impact of bile salts on telaprevir nucleation rate 
is greater than the impact on telaprevir crystal growth rate. That is to say, the assumption of 
nucleation time tn being the predominant factor in the induction time tind may be applied in this 
study, allowing evaluation of nucleation inhibition of bile salts with the measured crystallization 
induction time. Moreover, the preliminary results from Figure 11 reveal the potential of bile salts 
as crystal growth inhibitors, which is clearly an area for future study.  
Mechanistic Understanding of Bile Salt Inhibition Properties 
Bile salts are endogenous species in human gastrointestinal tract, and their solubilization 
and crystallization inhibition properties potentially play a direct role on API in vivo performance. 
Although there are at least six different bile salts in human intestinal fluid,17 STC is still the only 
bile salt component in common current simulated fluid recipes,34 and this possibly contributes to 
the observed discrepancy between some in vivo and in vitro tests noted in the literature.35 Therefore, 
having a better understanding of the impact of biologically relevant bile salts on crystallization 
kinetics of supersaturated API solutions is critical for formulation design. In supersaturated 
solutions, a longer crystallization induction time in the presence of additives could result from two 
factors: solubilization and/or intermolecular interactions that directly modify the nucleation 
process. For additives that solubilize the model compound, the increase in crystalline solubility 
leads to a decrease in supersaturation; therefore, a lower crystallization driving force exists in the 
presence of solubilizing additives under constant solution concentration.23 Besides solubilization, 
additives can interfere with the nuclei formation process and thus slow down crystallization of the 
model compound. 10, 36-38 Compared to general amphiphilic surfactants, it has been noted that bile 
salts have a lower solubilization capacity.11, 12, 39 That is to say, the delayed solution crystallization 
in the presence of bile salts is more likely to be a result of intermolecular interactions. 
In this study, supersaturation levels in the presence of bile salts were carefully calibrated 
and all crystallization studies were performed at equivalent driving forces. Ruling out 
solubilization as a factor in the prolonged crystallization induction times enables better 
mechanistic understanding of bile salt inhibition properties.  As summarized in Figures 4 and 5, 
the ability to retard telaprevir nucleation varies not only with structural differences amongst the 
bile salts, but also with their aggregation levels for the same crystallization driving forces. From 
Figure 4, it is evident that all monomeric bile salts in this study are effective crystallization 
inhibitors for telaprevir at the lower supersaturation employed. The good crystallization inhibitory 
ability of monomeric bile salts has been noted in other studies.11-13 As bile salt concentration 
increased above the CMC, some structural dependence, mainly related to the number of hydroxyl 
groups on the steroid ring, was observed amongst the bile salts. For trihydroxy bile salts, STC and 
SGC, the ability to retard telaprevir nucleation persisted with increasing bile salt concentration, 
even with the presence of micelles. An analogous nucleation inhibition behavior was reported in a 
previous study with another poorly soluble compound celecoxib.11 In this study, a more than ten-
fold increase in celecoxib crystallization induction time was observed in the presence of STC at 
concentrations below and above its CMC, suggesting that the presence of micellar STC does not 
promote celecoxib crystallization. Li et al.13 made similar observations for celecoxib regarding the 
STC concentration dependent crystallization inhibitory effect. In the same study, STC was also 
noted to slow down solution crystallization of nevirapine, another poorly soluble compound, even 
at bile salt concentrations above CMC. It was suggested that the step-wise aggregation behavior 
of STC is a possible reason for higher variations in nucleation inhibition properties observed for 
nevirapine at STC concentrations above its CMC. The observation of the inhibitory impact of 
solutions containing both free and micellar bile salts on crystallization kinetics is opposite to that 
observed for surfactants with a chain-like hydrophobic tail, such as sodium dodecyl sulfate,11, 39 
Polysorbate 80,11 and Poloxamer 188,11 where enhanced crystallization was observed. It was 
proposed that STC has a different impact on crystallization than conventional surfactants because 
of  the bulky hydrophobic group and rigid structure.11  
While trihydroxy bile salts still demonstrate inhibitory ability for homogeneous 
supersaturated solutions as the bile salt concentration increased to 12mM, a notable reduction in 
the extent of retardation of telaprevir nucleation was observed for the dihydroxy bile salts (Figure 
4). A similar trend was observed when the supersaturation level was elevated (Figure 5), where 
trihydroxy bile salts showed improved inhibitory ability at 12mM concentration, while the 
dihydroxy bile salts were less effective inhibitors when micelles were present. Trihydroxy bile 
salts have higher CMC values than dihydroxy bile salts, as noted from the literature16, 40, 41 and 
confirmed by our experimental data (Figure 6). That is to say, there should be a higher percentage 
of monomer, which we note is the effective crystallization inhibitory species (Figure 7), present at 
a 12mM bile salt concentration for trihydroxy bile salts than for dihydroxy bile salts, and 
correspondingly less aggregated bile salt. A higher concentration of the effective crystallization 
inhibitor, i.e. the monomer, at the same bile salt concentration is a possible contributing factor with 
regards to the persistent, or even improved, crystallization inhibitory ability of trihydroxy bile salts 
compared to dihydroxy bile salts. Moreover, Anwar et al.38 commented in a molecular simulation 
study that amphiphilic additives can inhibit nucleation via influencing the packing of the emerging 
nuclei structure if the solute±additive interaction is relatively strong. This explanation might be 
relevant for SGCDC, the only dihydroxy bile salt that was shown to be effective in inhibiting 
telaprevir crystallization even in the presence of micelles (Figure 4), as it was noted previously to 
have stronger intermolecular interactions with telaprevir.24 Alternatively, we can speculate that 
bile salt micelles promote crystallization by providing interfaces that act as heterogeneous 
nucleation sites. Therefore, the dihydroxy bile salt 12mM solutions, which contain more micellar 
species due to the lower CMC relative to the trihydroxy bile salts, may have both inhibitory and 
promoting species present. To further confirm our hypothesis of bile salt micelles negating the 
inhibitory impact of the monomers, induction time experiments were performed at į=11.5 in the 
presence of 18mM of STC and SGC. The supersaturated solutions all crystallized within 16 hours; 
at 12mM bile salt concentration, no crystallization was observed within 16 hrs (Figure 4). Given 
that there are more micelles present in the solution at 18mM bile salt concentration, this 
observation supports our contention that micelles oppose the inhibitory effect of monomers and 
lead to faster crystallization kinetics at higher bile salt concentrations. 
 For a highly supersaturated solution in the presence of a drug-rich phase, crystallization 
kinetics are expected to be facilitated as there are more interfaces present, enabling heterogeneous 
nucleation.25 This impact of the drug-rich phase, which has been previously characterized to have 
a size of around 300nm,42 on the crystallization kinetics can be readily seen by replotting the data 
shown in Figures 4 and 5 to enable a comparison of supersaturation level at equivalent bile salt 
concentrations, Figure 8 (monomer) and Figure 9 (micellar). Supersaturated solutions containing 
a telaprevir-rich phase and no inhibitors crystallized immediately. However, the presence of bile 
salts (both monomer and micellar levels) slowed down the crystallization kinetics (Figures 8 and 
9), suggesting that bile salts interact with the drug-rich phase, as supported by zeta potential 
measurements (Figure 10). Zeta potential is commonly employed to evaluate colloidal stability,43-
45 and it is well known that adsorption of ionized species can change the measured zeta potential.46-
48  As shown in Figure 10, the highly supersaturated telaprevir solutions containing drug-rich 
droplets have a small negative zeta potential, hence a high tendency for aggregation. 43, 44 With the 
addition of 1.86mM bile salts, the zeta potential of these systems decreased to around -50mV, and 
can be considered to be electrostatically stabilized.43, 44 From these results, it is evident that that 
all six bile salts interacted with the surface of the telaprevir-rich droplets as zeta-potential 
decreased significantly. This evidence of bile salt interaction with the drug-rich phase helps 
explain the observed inhibitory effect of bile salts on crystallization in these systems, since the 
presence of the bile salt at the particle-water interface can be expected to modify heterogeneous 
nucleation. However, it should be noted that the use of zeta-potential measurements in this work 
can only provide qualitative evidence of interfacial telaprevir-bile salt interactions, and is not a 
quantitative measure of the extent of absorption, as zeta-potential measurements have 
contributions from both physically adsorbed and chemically absorbed ions within the slip plane at 
the solid-solution interface. Hence, additional studies are needed to better understand and relate 
the crystallization inhibitory effect amongst different bile salts in these complex two phase 
solutions. 
To help summarize our observations on bile salt retardation of telaprevir nucleation 
kinetics, the various supersaturation and aggregation levels used in this study are shown in 
schematic form in Figure 12. Our experimental results suggest that 1) all of the monomeric bile 
salts evaluated are effective crystallization inhibitors, in particular in homogenous solutions of 
telaprevir (Figure 4, bottom left quadrant of Figure 12), 2) micelles of dihydroxy bile salts, with 
the exception of SGCDC, appear to negate the inhibitory impact of the monomers (Figure 4, top 
left quadrant Figure 12 ), 3) monomeric trihydroxy bile salts are less effective inhibitors in the 
presence of a drug-rich phase as compared to the dihydroxy bile salts studied (Figure 8, bottom 
right quadrant Figure 12), 4) in the presence of both micellar bile salt and a drug-rich phase, the 
pattern of inhibitory effects is complex, unpredictable and more work is clearly needed to 
investigate these systems (Figure 9, top right quadrant Figure 12). Moreover, these are probably 
the most relevant systems since micellar species are present in vivo, and many formulations have 
the potential to form a drug-rich phase following dissolution.22 To the best of our knowledge, very 
limited understanding and exploration of the role of micellar bile salts in the context of solution 
crystallization exist in the literature. Given the fact that bile salts are present in the human GI tract 
in the form of mixed micelles, this study provides important insights into the potential role of a 
more biorelevent bile salt aggregation state as well as a foundation to study more complex bile salt 
forms, e.g., mixed micelles with lecithin. 
It has been demonstrated that bile salts are not interchangeable from either a solution 
thermodynamics24 or a crystallization inhibition standpoint,13 and observations are of high 
significance in terms of selection of appropriate biorelevant dissolution media with predictive 
capabilities of in vivo API formulation performance, in particular in terms of crystallization 
kinetics. Based on observations made in this study, STC may not be a good surrogate for the 
mixture of bile salts found in vivo in terms of understanding the crystallization tendency of a given 
system. 
Potential as Crystallization Inhibitor ± A Comparison with Other Additives 
The potential of bile salts as crystallization inhibitors is of particular interest since they are 
endogenous species that share the advantages possessed by commonly employed formulation 
additives, such as surfactants and polymers. Surfactants solubilize hydrophobic molecules by 
incorporating them into micelles. This enhanced solubility is often achieved in the expense of drug 
membrane transport since less free drug (i.e. molecularly dissolved drug) is available in the 
presence of micelles for a given concentration.3, 23 Polymers, on the other hand, at the 
concentrations typically employed, have negligible impact on API crystalline solubility10, 31 and 
membrane transport rate.31 Based on previous studies,11-13, 24 bile salts are less effective 
solubilizing agents compared to conventional surfactants; however, these have been shown to 
promote crystallization of supersaturated solutions of poorly soluble compounds.11, 39 In contrast, 
polymers are often used as crystallization inhibitors, and improve the bioavailability of APIs 
through stabilizing the drug in the ASDs and the resultant highly supersaturated solutions.20, 49, 50 
Bile salts also decrease solution crystallization kinetics of poorly water soluble APIs, even at 
concentrations above their critical micelle concentrations.11-13  A comparison of the crystallization 
inhibitory effect of monomeric bile salts (1.86mM) and a commercially available polymer, 
HPMCAS-MF, at comparable supersaturation levels is provided in Figure 13. Mosquera-Giraldo 
et al.,37 showed that HPMCAS-MF is one of the most effective inhibitors of telaprevir amongst 
the multiple polymers studied. In the context of our study, biologically relevant bile salts showed 
comparable inhibition to HPMCAS-MF in homogenous solutions where all additives were 
extremely effective. In the presence of a drug-rich phase, HPMCAS-MF was better than the least 
effective bile salt, but not as effective as the best bile salt at inhibiting crystallization. The 
comparable inhibition ability of bile salts and polymers can also been seen by reviewing various 
literature studies on celecoxib crystallization.10, 13, 50 More detailed experimental and molecular 
modeling studies of how bile salts disrupt the API crystallization process are required in order to 
understand how different bile salt-drug interactions contribute to the observed differences in 
nucleation retardation ability. Nevertheless, it is clear that understanding the anti-nucleation 
properties of bile salts is important in the context of improving API formulation design and testing 
approaches. In addition, bile salts are unique species from both a solubilization and crystallization 
inhibition standpoint. 
CONCLUSIONS 
In this study, the impact of six biologically relevant bile salts on telaprevir crystallization 
induction time was evaluated at different bile salt aggregation levels. By carefully calibrating the 
supersaturation to maintain the same crystallization driving force, differences in the inhibitory 
effects of the bile salts were noted. For telaprevir supersaturated solutions below the amorphous 
solubility, monomeric bile salts were extremely effective inhibitors. Interestingly, the presence of 
bile salt micelles opposed the monomeric inhibitory effect for some of the bile salts. Telaprevir 
solutions above the amorphous solubility also showed delayed crystallization in the presence of 
both monomeric and micellar bile salts, but had a much higher tendency to crystallize in general. 
Importantly, it was observed that the bile salts are not interchangeable with respect to their ability 
to inhibit crystallization. In addition, these biologically relevant bile salts, in monomeric form, 
showed a comparable nucleation inhibition ability to hydroxypropylmethyl cellulose acetate 
succinate, a commonly employed crystallization inhibitor. Based on these observations, further 
studies of how bile salts impact the crystallization kinetics of drugs are essential in order to design 
biopredictive dissolution media and better predict in vivo behavior of supersaturating systems. 
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FIGURES  
 
Figure 1. Molecular structures of telaprevir and bile salts. 
 
Figure 2. Telaprevir concentrations under constant supersaturation levels in the absence and 
presence of bile salts. The mass flow rate data from our previous study were used for 
determination of telaprevir supersaturation level in solutions containing different bile salts.24 
  
Figure 3. Crystallization induction time of a supersaturated telaprevir solution was determined as the time 
when a sudden increase in extinction signal and a sudden decrease in apparent concentration was 
observed. 
 
Figure 4. Induction time for telaprevir at supersaturation level of į=11.5, in the absence and 
presence of predissolved 1.86mM and 12mM bile salts. 
 
 
Figure 5. Induction time for telaprevir at supersaturation level of į=28.8, in the absence and 
presence of predissolved 1.86mM and 12mM bile salts. 
 
 
 
Figure 6a. CMC of STC in the absence and presence of telaprevir as determined by measuring 
solution surface tension as a function of STC concentration. 
 
 
Figure 6b. CMC of SGDC in the absence and presence of telaprevir as determined by measuring 
solution surface tension as a function of SGDC concentration. 
 
  
 
Figure 7. Effect of STC concentration on induction time with 6ȝJP/telaprevir į .  
 
 
 
Figure 8. Induction time for telaprevir in the absence and presence of predissolved 1.86mM bile 
salts. Homogeneous solutions are at a concentration below the amorphous solubility of 
telaprevir, while GLPS refers to solutions just above the amorphous solubility of telaprevir 
which contain small (~300nm)42 amorphous telaprevir particles. Induction time results for 
solutions containing STCDC and SGCDC at į=28.8 were not reported as the same 
supersaturation level cannot be reached due to partitioning of these two bile salts into telaprevir-
rich phase.24 
 
 
 
  
Figure 9. Induction time for telaprevir in the absence and presence of predissolved 12mM bile 
salts. Induction time results for solutions containing STCDC and SGCDC at į=28.8 were not 
reported as the same supersaturation level cannot be reached due to partitioning of these two bile 
salts into telaprevir-rich phase.24 
 
 
 
 
Figure 10. Zeta potential of highly supersaturated telaprevir solution in the absence and presence 
of 1.86mM bile salts. 
 
 
 
 Figure 11. Desupersaturation profile of seeded telaprevir solution in the absence and presence of 
1.86mM STC, and 1.86mM SGC. The slope of the initial desupersaturation profiles (t < 10min) 
was used to determine the mass growth rate.   
 
 
 
 
 
Figure 12. Schematic description of the competing effect of monomeric and aggregated bile salts 
for supersaturated telaprevir solutions above (containing amorphous drug-rich nanodroplets) and 
below (homogeneous solution) the amorphous solubility. 
 
 
 Figure 13. Induction time for telaprevir in the absence and presence of predissolved bile salts (at 
1.86mM concentration) and the polymer, HMPCAS-MF (at 5ȝg/mL and 1mg/mL 
concentration). 
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